MedTrace Logo

Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease

NCT02929030 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2016-12-30

No results posted yet for this study

Summary

The study aims to evaluate the safety and efficacy of polymer-free sirolimus-eluting coronary stent system (NANO plus) in patients with coronary artery disease . The primary endpoint is target lesion failure, a composite endpoint of cardiac death, target vessel related myocardial infarction and clinically-driven target lesion revascularization at 1 year follow-up.

Conditions

Interventions

DEVICE

Nano

The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Lin Tao, PhD · Xijing Hospital

  • Yao-Jun Zhang, PhD · Nanjing First Hospital, Nanjing Medical University

  • Yue Li, PhD · The First Clinical Hospital affiliated to Harbin Medical University

  • Zhiqi Sun, PhD · Daqing oilfield central hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2018-01-31
Completion
2022-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02929030 on ClinicalTrials.gov